Outcome Analysis of Aspirin in Liver Transplantation

NCT04327427 | Unknown

• 1 other identifier: 2017-01889
• Study Type: observational
• Target: 3,000
• Locations: 1 country
• Sites: 1

Brief Summary

In the experimental setting inhibition of platelet activation was able to reduce immune-mediated necroinflammatory liver disease and consecutively hepatocellular carcinoma development. Therefore, antiplatelet therapy may not only have a preventive effect on hepatic artery patency but also on tumor recurrence. So far and to the best of our knowledge, no study investigated the effect of antiplatelet therapy on hepatic arterial patency, tumor recurrence and graft survival after primary liver transplantation.

Conditions

Liver Transplant; Complications

Keywords

liver transplantation; aspirin; tumor recurrence; HCC; graft survival

Outcome Measures

Primary Outcomes (1)

• Aspirin and arterial patency

  We will look, if antiplatelet therapy with Aspirin has a protective effect on arterial patency after primary liver transplantation by looking at postoperative lab values and imaging, if they were perfromed.

  2 years

Secondary Outcomes (3)

• Aspirin and cellular rejection

  2 years

• Aspirin and tumor recurrence

  2 years

• Aspirin and graft survival

  2 years

Interventions

Aspirin OTHER

Outcome Analysis of Aspirin in liver transplantation

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

This multicentrecohort study will include several high-volume centresworldwide. Each participating centrerequires a prospective database from that data can be extracted. All consecutive cases of deceased donor liver transplantation requiring from 1stofJanuary 2013until 31stof December 2015are included allowing a minimum follow-up time of 24months.

You may qualify if:

• Adult Liver transplantation(age ≥18 years)
• Deceased donor after brain death (DBD) or deceased donor after circulatory death (DCD)
• Primary liver transplantation, whole graft
• Arterial anastomosis: end-to-end, back table reconstruction

You may not qualify if:

• Split liver and living donor liver transplantation
• Paediatric liver transplantation (recipient age \<18 years)
• Arterial conduits
• Multivisceral transplantations
• Retransplantations

Sponsors & Collaborators

• University of Zurich: lead

Study Sites (1)

Department of Visceral and Transplantation Surgery

Zurich, CH/Zürich, 8091, Switzerland

RECRUITING

MeSH Terms

Conditions

Recurrence

Interventions

Aspirin

Condition Hierarchy (Ancestors)

Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Salicylates; Hydroxybenzoates; Phenols; Benzene Derivatives; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals

Study Officials

• Christian E Oberkofler, MD

  University of Zurich

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Christian E Oberkofler, MD

CONTACT

0041792961264; christian.oberkofler@usz.ch

Henrik Petrowsky, MD

CONTACT

0041794816199; henrik.petrowsky@usz.ch

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 17, 2020
• First Posted: March 31, 2020
• Study Start: October 1, 2019
• Primary Completion: October 1, 2020
• Study Completion: May 31, 2021
• Last Updated: March 31, 2020

Record last verified: 2020-03

Data Sharing

• IPD Sharing: Will not share

Locations

CH (1)